New cancer pill enters first human trials for Tough-to-Treat tumors
NCT ID NCT07229898
Summary
This is the first study in people testing a new oral medication called GEN-725 for advanced solid tumors that have progressed after standard treatments. The main goals are to find a safe dose, see how the drug moves through the body, and check for any early signs that it might help shrink tumors. It will enroll 48 adults with various advanced cancers, including lung, liver, and colorectal cancer, who have limited treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)
RECRUITINGJinan, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
-
Shanghai East Hospital
RECRUITINGShanghai, China
-
The First Affiliated Hospital of Xinxiang Medical University
RECRUITINGXinxiang, China
Conditions
Explore the condition pages connected to this study.